11/28
08:06 pm
blrx
BioLine Rx Ltd (BLRX) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... [Yahoo! Finance]
Medium
Report
BioLine Rx Ltd (BLRX) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... [Yahoo! Finance]
11/24
07:00 am
blrx
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Neutral
Report
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/21
09:32 am
blrx
BioLineRx Q3 2025 Earnings Preview [Seeking Alpha]
Low
Report
BioLineRx Q3 2025 Earnings Preview [Seeking Alpha]
11/19
03:51 am
blrx
Hemispherian Announces USPTO Notice of Allowance for Key GLIX1 Patent Covering Majority of Solid Tumors [Yahoo! Finance]
Medium
Report
Hemispherian Announces USPTO Notice of Allowance for Key GLIX1 Patent Covering Majority of Solid Tumors [Yahoo! Finance]
11/19
03:00 am
blrx
Hemispherian Announces USPTO Notice of Allowance for Key GLIX1 Patent Covering Majority of Solid Tumors
Medium
Report
Hemispherian Announces USPTO Notice of Allowance for Key GLIX1 Patent Covering Majority of Solid Tumors
11/18
07:00 am
blrx
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025
Medium
Report
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025
11/17
07:10 am
blrx
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types [Yahoo! Finance]
Medium
Report
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types [Yahoo! Finance]
11/17
07:00 am
blrx
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
Medium
Report
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
9/30
01:05 pm
blrx
BLRX: A Venture into GBM [Yahoo! Finance]
Neutral
Report
BLRX: A Venture into GBM [Yahoo! Finance]
9/29
07:26 am
blrx
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers [Yahoo! Finance]
Low
Report
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers [Yahoo! Finance]
9/29
07:00 am
blrx
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers
Medium
Report
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers